CGEM
Cullinan Therapeutics, Inc.Company Information
- Company Name
- Cullinan Therapeutics, Inc.
- CIK
- CIK0001789972
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CGEM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CGEM
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-28
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 475,182
- Shares sold (TTM)
- 162,012
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 68,182,918
- Shares outstanding
- 61,493,000
- Ownership
- 110.88%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 20.89%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 79 | 75 | 88 | 103 | 73 | 77 | 83 | 102 | 115 | 74 | 98 | 65 | ||||||
| Short Term Investments | 256 | 277 | 290 | 229 | 193 | 227 | 316 | 476 | 547 | 359 | 369 | 402 | ||||||
| Prepaid Expense Current | 7 | 10 | 9 | 10 | 10 | 14 | 16 | 14 | 15 | 13 | 13 | 10 | ||||||
| Assets Current | 342 | 361 | 387 | 342 | 276 | 318 | 415 | 592 | 678 | 446 | 480 | 477 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Investments | 19 | 39 | 58 | 140 | 242 | 259 | 204 | 58 | - | - | 0 | 14 | ||||||
| Assets | 364 | 403 | 448 | 484 | 520 | 580 | 622 | 653 | 681 | 449 | 484 | 495 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 2 | 1 | ||||||
| Accrued Liabilities Current | 36 | 32 | 36 | 30 | 24 | 23 | 28 | 21 | 21 | 17 | 24 | 21 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 41 | 35 | 38 | 33 | 28 | 27 | 31 | 24 | 23 | 22 | 28 | 23 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 42 | 37 | 40 | 33 | 28 | 28 | 31 | 25 | 25 | 24 | 30 | 26 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,013 | 1,004 | 996 | 988 | 978 | 968 | 959 | 947 | 937 | 664 | 655 | 647 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 1 | 1 | 1 | 1 | -0 | 1 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -691 | -638 | -588 | -537 | -487 | -417 | -368 | -321 | -280 | -238 | -201 | -177 | ||||||
| Stockholders Equity | 322 | 366 | 409 | 451 | 492 | 552 | 590 | 628 | 656 | 426 | 454 | 469 | ||||||
| Minority Interest | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 364 | 403 | 448 | 484 | 520 | 580 | 622 | 653 | 681 | 449 | 484 | 495 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 64 | 61 | 60 | 59 | 59 | 59 | 59 | 58 | 58 | 43 | 43 | 43 | ||||||
| Shares Outstanding | 64 | 61 | 60 | 59 | 59 | 59 | 59 | 58 | 58 | 43 | 43 | 43 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCullinan Therapeutics, Inc. (CGEM) — SEC Financial Statements & Analysis
Cullinan Therapeutics, Inc. (CGEM) is a biological products, (no diagnostic substances) company, incorporated in DE. Cullinan Therapeutics, Inc. trades on Nasdaq as: CGEM. Cullinan Therapeutics, Inc. (CGEM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Cullinan Therapeutics, Inc. carries a market cap of $1.12B, a P/E ratio of -5.45x, a P/B ratio of 3.48x, an enterprise value of $1.04B, and an EV/EBITDA multiple of -4.70x. On profitability, it posts a Return on Equity (ROE) of -50.45%, a Return on Assets (ROA) of -46.45%, and a Return on Invested Capital (ROIC) of -66.97%. Per share, it reports EPS of $-3.34, diluted EPS of $-3.34, free cash flow per share of $-2.59, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 1.66% year-over-year and EPS growth of -2.44% year-over-year. On the balance sheet, it maintains a current ratio of 8.42x, a quick ratio of 8.23x, working capital of $301.35M, a debt-to-equity ratio of 0.13x, a debt ratio of 0.12, free cash flow of $-159.30M (TTM), and net debt of $-78.64M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.12B
- P/E TTM
- -5.45x
- EPS TTM
- $-3.34
- P/B TTM
- 3.48x
- ROE TTM
- -50.45%
- ROA TTM
- -46.45%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $-159.30M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cullinan Therapeutics, Inc. in?
Cullinan Therapeutics, Inc. (CGEM) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CGEM trade on?
Cullinan Therapeutics, Inc. (CGEM) trades on the Nasdaq.
Where is Cullinan Therapeutics, Inc. incorporated?
Cullinan Therapeutics, Inc. is incorporated in DE.
When was Cullinan Therapeutics, Inc. (CGEM)'s most recent SEC filing?
Cullinan Therapeutics, Inc. (CGEM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CGEM's market cap?
Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.12B as of 2026-06-30.
What is CGEM's EPS (earnings per share)?
Cullinan Therapeutics, Inc. (CGEM)'s trailing twelve month EPS is $-3.34 as of 2026-06-30.
What is CGEM's ROE (return on equity)?
Cullinan Therapeutics, Inc. (CGEM)'s trailing twelve month Return on Equity (ROE) is -50.45% as of 2026-06-30.
What is CGEM's ROA (return on assets)?
Cullinan Therapeutics, Inc. (CGEM)'s trailing twelve month Return on Assets (ROA) is -46.45% as of 2026-06-30.
What is CGEM's ROIC (return on invested capital)?
Cullinan Therapeutics, Inc. (CGEM)'s trailing twelve month Return on Invested Capital (ROIC) is -66.97% as of 2026-06-30.
What is CGEM's EV/EBITDA?
Cullinan Therapeutics, Inc. (CGEM)'s trailing twelve month EV/EBITDA is -4.70x as of 2026-06-30.